[1]任延峰,杨 毅,明 坚,等.药品集中采购政策的WHO经验及启示[J].卫生经济研究,2022,39(6):17-19.
　REN Yanfeng,YANG Yi,MING Jian,et al.Experience of WHO about Volume-Based Drug Procurement Policy[J].Journal Press of Health Economics Research,2022,39(6):17-19.
点击复制

药品集中采购政策的WHO经验及启示
分享到：

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
39
期数:
2022年6期
页码:
17-19
栏目:
药械管理
出版日期:
2022-05-26

文章信息/Info

Title:
Experience of WHO about Volume-Based Drug Procurement Policy
作者:
任延峰1; 杨 毅1; 明 坚1; 2; 孙 辉1; 3; 刘 柳1; 鲍诗意1; 陈英耀1
1.复旦大学公共卫生学院，国家卫生健康委员会卫生技术评估重点实验室（复旦大学），上海 200032
2.艾昆纬企业管理咨询（上海）有限公司，上海 200041
3.上海市卫生和健康发展研究中心，上海 200040
Author(s):
REN Yanfeng;  YANG Yi;  MING Jian;  SUN Hui;  LIU Liu;  BAO Shiyi;  CHEN Yingyao
School of Public Health, Fudan University, NHC Key Laboratory of Health Technology Assessment (Fudan University), Shanghai 200032, China
关键词:
药品定价; 药品集中带量采购; 世界卫生组织
Keywords:
drug pricing;  volume-based drug procurement;  World Health Organization (WHO)
分类号:
R19
文献标志码:
A
摘要:
世界卫生组织于2020年发布的《国家药品定价政策指南》，对制定药品集中采购政策提出了许多有效建议，为我国药品集中采购政策的发展改革提供了启示：发挥政策协同作用，推动分类采购模式形成，完善集中采购药品质量评价体系，促进采购流程透明化，建立完善信息共享平台，持续监测药品质量。
Abstract:
The Guideline for National Drug Pricing Policy issued by the World Health Organization (WHO) in 2020 put forward many effective suggestions for formulating volume-based drug procurement policies, and provided inspiration for the development and reform of our country's volume-based drug procurement policies. It is suggested to enhance policy synergy and promote classified procurement models. It is also recommended to improve the quality evaluation system for volume-based drug procurement, promote the transparency of the procurement process, establish and improve the information sharing platform, and continuously monitor the quality of drugs.

参考文献/References:

[[1] 陈斌，徐洪斌，叶秀峰. 集中招标采购与国家谈判药品价格形成实证研究[J].中国医药科学，2021，11（12）：210-214.
[2] 傅鸿鹏. 药品集中招标采购的发展和展望[J].中国医疗保险，2020（3）：32-36.
[3] Barbosa K de S,Fiuza E.Demand aggregation and credit risk effects in pooled procurement：evidence from the Brazilian public purchases of pharmaceuticals and medical supplies[R].C-Micro Working Paper Series.Report No.299[C].Sao Paulo：Escola de Economia de Sao Paulo，Fundacao Getulio Vargas,2011.
[4] WHO.Multi-country regional pooled procurement of medicines[R].Geneva，Switzerland：2007.
[5] Seidman G，Atun R.Do changes to supply chains and procurement processes yield cost savings and improve availability of pharmaceuticals，vaccines or health products?A systematic review of evidence from low-income and middle-income countries[J].BMJ Glob Health，2017，2（2）:e243.
[6] “医保药品管理改革”蓝皮书发布[J].中国医院院长，2021，17（23）：20.
[7] 荆文娜.五次药品集采预计每年可节省药品费用926亿元[N].中国经济导报，2021-07-22（006）.
[8] 谭清立，杨思远，李文静，等. “4+7”药品带量采购的效果、关键问题与对策——基于广州的实践[J].卫生经济研究，2020，37（4）：46-50.
[9] 金春林，陈珉惺.分类分级采购格局正在成型[J].中国卫生，2020（6）：82-84.
[10] 胡善联.药品带量采购如何走向常态化制度化[N].医药经济报，2021-02-22（001）.
[11] 舒茜，姚峥嵘，王艳翚，等.药品带量采购政策的利益相关者分析[J].卫生经济研究，2019，36（8）：8-9.
[12] 刘迎堂，王梅. 新制度下药品集中招标采购制度的完善[J].中国药物经济学，2021，16（5）：18-21.
[13] 杜雪，马珺，黎雯霞. 药品带量采购存在的问题与对策分析[J].卫生经济研究，2020，37（8）：42-44.
[14] 周苑，汤质如，刘守明，等.药品集中采购模式研究及问题探讨[J].卫生经济研究，2018（3）：26-28.

相似文献/References:

[1]周 苑,汤质如,刘守明,等.药品集中采购模式研究及问题探讨[J].卫生经济研究,2018,(03):26.
[2]李 萍,汤少梁.后疫情时代药品集中带量采购政策制约因素与执行路径——基于史密斯政策执行模型[J].卫生经济研究,2021,38(4):32.
　LI Ping,TANG Shao-liang.The Restrictive Factors and Implementation Path of Drug Centralized Quantity Purchase Policy in the Post-epidemic Era——Based on Smith Policy Implementation Model[J].Journal Press of Health Economics Research,2021,38(6):32.
[3]郭 丽,王 健,王敬毅,等.药品集中采购政策对医院抗菌药物使用的影响研究[J].卫生经济研究,2022,39(6):24.
　GUO Li,WANG Jian,WANG Jingyi,et al.Effects of Volume-Based Procurement Policy on the Use of Antibiotics in Public Hospital[J].Journal Press of Health Economics Research,2022,39(6):24.
[4]周广进,常 峰,路 云.我国中成药集中带量采购政策研究[J].卫生经济研究,2023,40(6):18.
　ZHOU Guangjin,CHANG Feng,LU Yun.Study on the Policy of Centralized Volume-based Procurement of Chinese Patent Medicine in China[J].Journal Press of Health Economics Research,2023,40(6):18.
[5]马枋婷,常 峰,路 云,等.我国药品集中带量采购政策执行情况分析[J].卫生经济研究,2023,40(7):17.
　MA Fangting,CHANG Feng,LU Yun,et al.Analysis of the Implementation of National Centralized Drug Procurement Policy in China[J].Journal Press of Health Economics Research,2023,40(6):17.
[6]刘玉新,莫颖宁,郭德第.药品集中带量采购政策执行现状与接续建议——基于史密斯政策执行模型[J].卫生经济研究,2023,40(7):20.
　LIU Yuxin,MO Yingning,GUO Dedi.Implementation Situation and Continuation Suggestions of the Policy of Centralized Volume-based Procurement of Drugs ——Based on Smith Policy Implementation Process Model[J].Journal Press of Health Economics Research,2023,40(6):20.
[7]王 彪,廖 鹏,唐啸宇,等.国家集中带量采购中选药品的供应短缺问题研究[J].卫生经济研究,2024,41(02):40.
　WANG Biao,LIAO Peng,TANG Xiaoyu,et al.Study on the Supply Shortage of Selected Drugs in National Centralized Volume-based Procurement[J].Journal Press of Health Economics Research,2024,41(6):40.
[8]段凤然,文小桐,王 越,等.集采政策对医疗机构心血管药品采购的影响研究[J].卫生经济研究,2024,41(03):69.
　DUAN Fengran,WEN Xiaotong,WANG Yue,et al.Study on the Impact of Centralized Volume-based Procurement Policy on the Procurement of Cardiovascular Drugs in Medical Institutions[J].Journal Press of Health Economics Research,2024,41(6):69.
[9]宋 菲,陈 昊,王晨舟,等.国家药品集采对儿童用药供应保障的影响分析[J].卫生经济研究,2024,41(10):10.
　SONG Fei,CHEN Hao,WANG Chenzhou,et al.Analysis of the Impact of National Centralized Volume-based Procurement of Drugs on the Supply Guarantee of Children's Drugs[J].Journal Press of Health Economics Research,2024,41(6):10.
[10]冼学国,杨 勇,黄 坚,等.儿童用药视角下国家药品集中采购政策实施效果探析[J].卫生经济研究,2024,41(10):15.
　XIAN Xueguo,YANG Yong,HUANG Jian,et al.Analysis of the Implementation Effect of the Policy for National Centralized Volume-based Procurement of Drugs from the Perspective of Children's Drugs[J].Journal Press of Health Economics Research,2024,41(6):15.

更新日期/Last Update: 2022-05-26